Navigation Links
The Leukemia & Lymphoma Society Applauds FDA's Approval of Idelalisib To Treat Three Types of Blood Cancers
Date:7/23/2014

WHITE PLAINS, N.Y., July 23, 2014 /PRNewswire-USNewswire/ -- Today's U.S. Food and Drug Administration (FDA) approval of idelalisib to treat patients with relapsed chronic lymphocytic leukemia (CLL), follicular lymphoma (FL) and small lymphocytic lymphoma (SLL) is a significant advance for patients with these blood cancers. 

Idelalisib, which goes by the trade name Zydelig®, is a first-in-class inhibitor of PI3K delta, a protein that is highly expressed in many B-cell malignancies and plays a critical role in the viability, proliferation and migration of these cancer cells.

Idelalisib is an oral therapy indicated in combination with rituximab, a monoclonal antibody, for patients with relapsed or refractory CLL for whom rituximab alone would be considered appropriate therapy. In October 2013, a Phase 3 study evaluating idelalisib in combination with rituximab in previously-treated CLL patients not fit for standard chemotherapy was stopped early because interim analysis was showing significant improvement in progression-free survival as well as median overall survival compared to placebo plus rituximab.

Idelalisib was also approved today as a monotherapy for patients with relapsed FL and SLL who have received at least two prior systemic therapies. FDA granted accelerated approval for FL and SLL based on overall response rate. 

"We have been eagerly awaiting the approval of this therapy as these are patients for whom there are few other good treatment options," said Lee Greenberger, Ph.D., LLS's chief scientific officer. "LLS funded research contributed to the understanding of the PI3K pathway in B cell malignancies beginning in 1999; this allowed the identification and clinical development of inhibitors of this target. LLS exists to find cures and ensure access to treatments for blood cancer patients, and any new advance that brings the potential to help save more li
'/>"/>

SOURCE The Leukemia & Lymphoma Society
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. BioLineRx Announces Promising Initial Phase 2 Results of Acute Myeloid Leukemia Treatment
2. The Leukemia & Lymphoma Societys (LLS) Greater Bay Area Chapter to Host the 2014 Emerging Therapies & Survivorship Conference
3. BioLineRx Presents Positive Preclinical Results of Acute Myeloid Leukemia Treatment at ASH Conference
4. Cell Therapeutics Announces Presentation of Interim Results from Phase 2 Tosedostat Trial in Older Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) at ASH Annual Meeting
5. Ibrutinib Data Published in The Lancet Oncology Suggest a Positive Effect in Previously Untreated Chronic Lymphocytic Leukemia Patients Over Age 65
6. New Study Finds Targeted Treatment Can Significantly Reduce Relapse Risk In High-Risk Children With Acute Myeloid Leukemia
7. Improved Efficacy, Limited Toxicity of Targeted Therapies Brighten the Future of Treatment for Chronic Lymphocytic Leukemia
8. Novartis highlights research on investigational, personalized T cell therapy CTL019 in patients with forms of acute and chronic leukemia
9. Polaris Group Files New IND for ADI-PEG 20 in Leukemia
10. The Leukemia & Lymphoma Society Applauds FDAs Approval of Ibrutinib for Certain Patients with Mantle Cell Lymphoma
11. Polaris Group Announces Treatment of First Patient in Phase 2 Study of ADI-PEG 20 in Acute Myeloid Leukemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today ... the second quarter ending June 30, 2015. ... organization.  We are excited to be near the completion ... conducted with topline results expected in the fourth quarter," ... Therapeutics, Inc. "Translarna is now commercially available in 12 ...
(Date:7/30/2015)... 30, 2015 Tianyin Pharmaceutical Inc. (NYSE Amex: ... specializes in the patented biopharmaceutical, modernized traditional Chinese medicine ... updates regarding the notice it received on May 21, ... that the Company was below certain of the Exchange,s ... and 1101 of the NYSE MKT Company Guide, due ...
(Date:7/30/2015)... LAKE, N.J. , July 30, 2015 ... simultaneously in the United States , ... the FDA, EMA and MHLW, respectively) for eribulin, for ... (STS) who have received prior chemotherapy for advanced or ... based on data from a pivotal global Phase 3 ...
Breaking Medicine Technology:PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 2PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 3PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 4PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 5PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 6PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 7PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 8PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 9PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 10TPI Provides Update Regarding Non-Compliance with NYSE MKT Continued Listing Requirements 2Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 2Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 3Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 4Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 5
... 27, 2011 Water Street Healthcare Partners , ... care, announced today that it has acquired MarketLab, ... firm,s fourth in the specialty healthcare distribution sector.  The ... companies specializing in distribution, life sciences, medical devices and ...
... 2011 Pacira Pharmaceuticals, Inc ., (Nasdaq: ... announced that it has been included in the Russell ... set of U.S. and global equity indexes on June ... measures the performance of the 3,000 largest U.S. companies ...
Cached Medicine Technology:Water Street Healthcare Partners Acquires MarketLab, Inc. 2Water Street Healthcare Partners Acquires MarketLab, Inc. 3Pacira Pharmaceuticals, Inc. Announces Inclusion in Russell 3000 Index 2Pacira Pharmaceuticals, Inc. Announces Inclusion in Russell 3000 Index 3
(Date:8/1/2015)... , ... August 02, 2015 , ... AlignLife ... will help the continuity of care for patients at this natural health care center ... unknown," Clinic Director Mary Heal said. "Heather's role is vital to our approach because ...
(Date:8/1/2015)... ... August 01, 2015 , ... Have you ever wondered what “Karma” really means? Does ... the word “Karma.” , Vedic tradition, which gave birth to Hinduism, is one of ... the central concepts of this tradition. According to the wisdom of this heritage, Karma is ...
(Date:8/1/2015)... ... 01, 2015 , ... Tina Wilcoxson, owner of Freeport Maine’s Royal River Natural ... by the National Retail Federation, the largest retail trade association in the world, for ... business owners to be named as such. According to the NRF’s website, Retail Champions ...
(Date:8/1/2015)... ... August 01, 2015 , ... On Tuesday, July 28th, Symantec ... are thought to have been behind the attack on Anthem Inc. which resulted in ... day exploits, watering hole attacks and spear phishing campaigns. , For Joe ...
(Date:8/1/2015)... , ... August 01, 2015 , ... “ reTXT ” ... at the latest and coolest applications on the market for iOS, Android, and Windows. ... shared with viewers allows users to clarify, edit and delete any message including ones ...
Breaking Medicine News(10 mins):Health News:New Patient Advocate Enhances Natural Health Care 2Health News:Nithyananda Yoga Foundation to Conduct Global Webinar on Karma at No Charge on August 1st 2Health News:Local Retail Advocate Wins National Recognition 2Health News:Frenemy at the Gates - Hackers Excel at Leveraging Trust 2Health News:Frenemy at the Gates - Hackers Excel at Leveraging Trust 3Health News:Frenemy at the Gates - Hackers Excel at Leveraging Trust 4Health News:Correct Auto-Correct and Clarify the Unclear with reTXT Messaging App 2
... realizes -- in basic biological development and, maybe, they ... to University of Oregon researchers. In a study ... UO Institute of Molecular Biology focused on the developing ... of its eggshell through the exposure to natural colonizing ...
... -- A Loyola University Hospital study has demonstrated how the ... the number of blood transfusions. In 2009, the average amount ... percent lower than it was in 2008, saving $453,355. The ... per patient in 2008 to 1.82 units per patient in ...
... nations when it comes to gains in life expectancy, and ... and homicideare not to blame, according to a study by ... study looked at health spending; behavioral risk factors ... and women ages 45 and 65 in the U.S. and ...
... (07 October 2010) To mark World Menopause Day ... is launching new Recommendations for the management of postmenopausal ... to half of women after menopause. This new ... in two women with vaginal atrophy (VA) will live ...
... The U.S. Department of Health and Human Services is ... Relief (PEPFAR) with a plan to invest $130 million ... dramatically increase the number of health care workers. ... grants are being awarded directly to African institutions in ...
... October 7, 2010The United States continues to lag behind ... expectancy, and commonly cited causes for our poor performanceobesity, ... to a Commonwealth Fund-supported study published today as a ... and Sherry Glied at Columbia University, looked at ...
Cached Medicine News:Health News:Gut microbes promote cell turnover by a well-known pathway 2Health News:Reducing blood transfusions improves patient safety and cuts costs 2Health News:Despite highest health spending, Americans' life expectancy falls behind other countries' 2Health News:Despite highest health spending, Americans' life expectancy falls behind other countries' 3Health News:International Menopause Society calls upon medical community to improve the vaginal health of postmenopausal women 2Health News:International Menopause Society calls upon medical community to improve the vaginal health of postmenopausal women 3Health News:HHS agencies partner with PEPFAR to transform African medical education 2Health News:HHS agencies partner with PEPFAR to transform African medical education 3Health News:HHS agencies partner with PEPFAR to transform African medical education 4Health News:HHS agencies partner with PEPFAR to transform African medical education 5Health News:Americans' life expectancy continues to fall behind other countries' 2Health News:Americans' life expectancy continues to fall behind other countries' 3
For the quantitative in vitro determination of Alanine Aminotransferase (ALT) in serum and plasma....
... Anteroir Cervical System, in conjunction with adjunctive ... collar), is intended for use in single ... as a means to maintain the relative ... This device is not intended to be ...
The Tag-It™ Cystic Fibrosis ASR reagents can be used by high complexity CLIA approved laboratories for detection of up to 70 mutations and 6 variants (polymorphisms) in the cystic fibrosis tran...
The Tag-It™ Cystic Fibrosis ASR reagents can be used by high complexity CLIA approved laboratories for detection of up to 70 mutations and 6 variants (polymorphisms) in the cystic fibrosis tran...
Medicine Products: